Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock

GlobeNewswire September 28, 2021

Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

GlobeNewswire September 24, 2021

Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire September 23, 2021

Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

GlobeNewswire September 22, 2021

Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit

GlobeNewswire September 20, 2021

Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 12, 2021

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021

GlobeNewswire August 5, 2021

Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer

GlobeNewswire June 28, 2021

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

GlobeNewswire June 22, 2021

Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade

GlobeNewswire June 17, 2021

Onconova Therapeutics Announces Participation in A.G.P.'s Upcoming Virtual Summer Healthcare Symposium

GlobeNewswire June 10, 2021

Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital

GlobeNewswire June 3, 2021

Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer

GlobeNewswire June 1, 2021

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

GlobeNewswire May 21, 2021

Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares

GlobeNewswire May 20, 2021

Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 17, 2021

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021

GlobeNewswire May 10, 2021

Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma

GlobeNewswire April 22, 2021

Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China

GlobeNewswire April 1, 2021